Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

CBD Offers Natural Relief for Pets

Lymphoma – Therapies CBD & Pioneering Breakthrough

Demons
12.06.2018

Content:

  • Lymphoma – Therapies CBD & Pioneering Breakthrough
  • Breakthrough treatment backed for non-Hodgkin lymphoma patients
  • Categories
  • has denied patients access to a 'pioneering', 'breakthrough', 'revolutionary' treatment. While this particular type of lymphoma doesn't have a standard therapy, yet, most . Sativex is a cannabis extract which contains both THC and CBD. New cancer drug appears to cure a third of terminal lymphoma patients the NHS has worked to make this pioneering treatment available so. CBD oil tumors. No pet owner ever wants to hear their dog has lymphoma–But . CBD & Lymphoma – Pioneering Breakthrough Therapies.

    Lymphoma – Therapies CBD & Pioneering Breakthrough

    Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on GVHD and treatment of acute and chronic pain.

    This press release may contain certain forward-looking information and statements "forward-looking information" within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives and other statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions.

    Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the ris k that future clinical studies may not proceed as expected or may produce unfavourable results. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results as applicable.

    Although Kalytera believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Kalytera's control. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof.

    Kalytera disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Search Now you can search stock related news and private companies such as Airbnb. No matching results for ''. Try a valid symbol or a specific company name for relevant results.

    Give feedback on the new search experience. In the second of the two prior Phase 2a clinical studies, 12 patients were administered CBD at a dose of mg administered twice daily from 7 days prior to the bone marrow transplant procedure until up to days post transplantation. Based on the positive and encouraging results from the two prior Phase 2a clinical studies that we completed in prevention of GVHD, we are optimistic that our CBD product will address this unmet need, and will be demonstrated to be a safe and effective means to prevent the onset of acute GVHD.

    We are planning to initiate a seamless Phase pivotal registration study in the treatment of acute GVHD later this year. There are currently few options to treat patients with acute GVHD, a critically underserved market. Our Phase pivotal registration study will enroll approximately patients and will assess the safety and efficacy of multiple doses of CBD for the treatment of acute GVHD.

    The study will be a multicenter, multinational, placebo controlled, randomized clinical trial, for the evaluation of the safety and efficacy of CBD for the treatment of grade acute GVHD. All ten patients in the Phase 2a clinical study were steroid refractory, meaning that they had not responded to previously administered standard of care steroid treatment. The study design was an open label, single arm, addition to standard of care treatment.

    Ten subjects, 18 years of age or older, participated in the study. The patients were administered a fixed oral dose of a highly pure formulation of CBD that was extracted from cannabis and dissolved in olive oil.

    The fixed dose of mg of CBD was administered twice daily for up to three months, alongside standard of care therapy. The results of this Phase 2a study were positive and highly encouraging.

    Nine of the ten patients responded to treatment, with seven achieving complete remissions, and with two achieving near-complete responses.

    Breakthrough treatment backed for non-Hodgkin lymphoma patients

    A breakthrough cancer treatment has been recommended for adults with some types of non-Hodgkin lymphoma. The National Institute for. Archive of cancer-related news briefs, by week, for The FDA granted Breakthrough Therapy designation to ribociclib (Kisqali; Novartis) for ASCO's highest scientific honor, for his pioneering research in CAR T cells, also called who were randomly assigned to receive THC:CBD or placebo as add-on therapy. February 22, ET | Source: Kalytera Therapeutics, Inc. allogeneic hematopoietic cell transplantation without CBD therapy study apply for both Breakthrough Therapy and Fast Track Designations, Hodgkin and Non- Hodgkin lymphoma, multiple myeloma, sickle cell anemia, and thalassemia.

    Categories



    Comments

    pvp1

    A breakthrough cancer treatment has been recommended for adults with some types of non-Hodgkin lymphoma. The National Institute for.

    yjuufyj

    Archive of cancer-related news briefs, by week, for The FDA granted Breakthrough Therapy designation to ribociclib (Kisqali; Novartis) for ASCO's highest scientific honor, for his pioneering research in CAR T cells, also called who were randomly assigned to receive THC:CBD or placebo as add-on therapy.

    avrilkinbafer2

    February 22, ET | Source: Kalytera Therapeutics, Inc. allogeneic hematopoietic cell transplantation without CBD therapy study apply for both Breakthrough Therapy and Fast Track Designations, Hodgkin and Non- Hodgkin lymphoma, multiple myeloma, sickle cell anemia, and thalassemia.

    wpZedWolf

    Cannabis is a well-regarded therapy for a number of diseases and disorders. like chemo or radiation therapy, Hodgkin's lymphoma has the potential to be a antiemetics tetrahydrocannabinol (THC) and cannabidiol (CBD).

    Add Comment